Who Paid My Doc
Michael Derevensky
Burlington, VT Medical Doctor
NPI 1740975689 CMS profile 11968036
111 Colchester Ave, Burlington, VT 05401
General payments
$67
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Michael Derevensky of Burlington, VT is reported in the CMS Open Payments database as having received $67 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $67 | 1 |
Beside peers
- Michael Derevensky
- Vermont median
- Middle half of Vermont
- National median
In program year 2025, general payments to Michael Derevensky were reported at $67. Among 430 Vermont profiles paid that year, the median was $119 and the middle half received between $39 and $763.
Show as a table
| Year | Michael Derevensky | Vermont median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $123 | $34–$988 | $163 |
| 2020 | $0 | $90 | $29–$627 | $114 |
| 2021 | $0 | $82 | $21–$371 | $132 |
| 2022 | $0 | $97 | $27–$459 | $149 |
| 2023 | $0 | $119 | $25–$623 | $160 |
| 2024 | $0 | $113 | $27–$738 | $164 |
| 2025 | $67 | $119 | $39–$763 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
68
Drug cost
$12,300
Branded share of claims
70.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Spiriva Respimat Tiotropium Bromide | Brand | 20 | $10,387 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 12 | $1,255 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 16 | $468 | |
| Atorvastatin Calcium | Generic | 20 | $190 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 30,207 Part D prescribers listed as Student in an Organized Health Care Education/Training Program; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.